Lilly(Eli) & Co (LLY) concluded trading on Thursday at a closing price of $801.65, with 3.49 million shares of worth about $2.8 billion changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -11.05% during that period and on March 13, 2025 the price saw a loss of about -2.46%. Currently the company’s common shares owned by public are about 947.54M shares, out of which, 850.00M shares are available for trading.
Stock saw a price change of -12.17% in past 5 days and over the past one month there was a price change of -7.32%. Year-to-date (YTD), LLY shares are showing a performance of 3.84% which increased to 9.16% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $711.40 but also hit the highest price of $972.53 during that period. The average intraday trading volume for Lilly(Eli) & Co shares is 3.69 million. The stock is currently trading -8.60% below its 20-day simple moving average (SMA20), while that difference is down -3.37% for SMA50 and it goes to -6.31% lower than SMA200.
Lilly(Eli) & Co (NYSE: LLY) currently have 947.54M outstanding shares and institutions hold larger chunk of about 72.97% of that.
The stock has a current market capitalization of $759.96B and its 3Y-monthly beta is at 0.51. PE ratio of stock for trailing 12 months is 69.77, while it has posted earnings per share of $11.49 in the same period. Its PEG reads 1.67 and has Quick Ratio of 0.89 while making debt-to-equity ratio of 2.37. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for LLY, volatility over the week remained 3.67% while standing at 2.91% over the month.
Stock’s fiscal year EPS is expected to rise by 76.68% while it is estimated to increase by 27.60% in next year. EPS is likely to grow at an annualized rate of 41.73% for next 5-years, compared to annual growth of 18.77% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by BofA Securities on December 10, 2024 offering a Buy rating for the stock and assigned a target price of $997 to it. Coverage by Wolfe Research stated Lilly(Eli) & Co (LLY) stock as an Outperform in their note to investors on November 15, 2024, suggesting a price target of $1000 for the stock. On October 17, 2024, Bernstein Initiated their recommendations, while on September 13, 2024, Citigroup Resumed their ratings for the stock with a price target of $1060. Stock get a Buy rating from Deutsche Bank on August 12, 2024.
